The Cardiovascular Actions of Protease-Activated Receptors

Susan F. Steinberg

Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York

Received May 21, 2004; accepted September 7, 2004

ABSTRACT
Protease-activated receptors (PARs) comprise a family of G protein-coupled receptors with a unique proteolytic activation mechanism. PARs are activated by thrombin or other coagulation or inflammatory proteases formed at sites of tissue injury. PARs play a particularly important role in the pathogenesis of clinical disorders characterized by chronic inflammation or smoldering activation of the coagulation cascade. Individual PARs have been linked to the regulation of a broad range of cellular functions. Recent studies identify PAR family members in the vasculature (including within atherosclerotic lesions) and in the heart. Here, PAR-triggered responses contribute to vasoregulation and influence cardiac electrical and mechanical activity. PAR activation also is linked to structural remodeling of the vasculature and the myocardium. This review focuses on the cardiovascular actions of PARs that play a role in normal cardiovascular physiology and that are likely to contribute to cardiovascular diseases.

Thrombin was first identified as a trypsin-like serine protease produced at sites of vessel injury or tissue damage, which plays a key role in blood coagulation by converting fibrinogen to fibrin (the fibrous matrix of blood clots). However, early studies exposed an additional effect of thrombin to promote platelet aggregation, even in the absence of any other coagulation factors. The molecular basis for the cellular actions of thrombin, distinct from its role in clot formation, was first elucidated by the Coughlin laboratory with the cloning of PAR-1 in 1991 (Coughlin, 2000). Subsequent research identified PAR-1 as a prototype of a family of related PARs that have important nonhemostatic functions in development, play a role in tumor biology, and orchestrate a series of highly regulated responses that are integral to the inflammatory response and are vital for normal tissue repair. The broad scope of cellular processes regulated by PARs is evident from the recent excellent reviews that consider roles for PARs in inflammation and wound healing, vasoregulation, angiogenesis, atherosclerosis, gastrointestinal disorders, pain perception by sensory neurons, airway hyper-reactivity, and inflammatory pulmonary diseases (Vergnolle, 2000; Macfarlane et al., 2001; Vergnolle et al., 2001; Major et al., 2003; Ossovskaya and Bunnett, 2004). PARs also exert a wide range of cardiovascular actions. Most of the published literature has focused on PAR-mediated action in platelets and the vasculature. Here, PARs are critical for normal hemostasis and contribute to the pathogenesis of vascular disorders characterized by chronic inflammation or smoldering activation of the coagulation cascade (including vascular atherosclerosis). However, there is recent evidence that PARs also exert direct effects on the heart that lead to changes in contractile performance and structural remodeling of ventricular cardiomyocytes. This review briefly summarizes the pharmacological properties of the four known PAR family members before focusing on recent literature that explores the cardiovascular consequences of PAR activation.

PAR Structure and Activation Mechanisms

PAR-1. PAR-1 is the prototype for the family of G protein-coupled heptahelical receptors (GPCRs) that are activated via limited N-terminal proteolysis by serine proteases...
Thrombin (the physiological activator of PAR-1) docks to two sites on the PAR-1 N terminus. The initial interaction is between the anion-binding recognition site of thrombin (anion-binding exosite I) and a negatively charged hirudin-like surface on PAR-1 (DK51YEPF55) (Figs. 1 and 2). This high-affinity interaction is believed to induce a conformational change that facilitates thrombin binding (via its catalytic site) to the PAR-1 cleavage sequence (LDPR41S42FLLRN), an interaction energetically favored when the P2 and/or P4 positions of the P4–P1 sequence is occupied by proline residues (Jacques and Kuliopulos, 2003). PAR-1 cleavage exposes a new N terminus beginning with SFLLRN (human sequence) that acts as a tethered peptide ligand.

The proteolytic mechanism for PAR-1 activation can be bypassed entirely with a synthetic peptide that corresponds to the newly exposed N-terminal tethered ligand sequence. However, PAR-1 activation requires relatively high concentrations of soluble agonist peptide (AP) (10–20 μM); in contrast, picomolar thrombin is sufficient to proteolytically activate PAR-1 (Table 1). These differences generally have been attributed to the lack of a membrane tether; soluble APs need not assume the correct orientation relative to the ligand recognition sites, and they also are likely to be more susceptible to the actions of degradative enzymes.

Current models hold that PAR-1 activation results from a docking interaction between the basic arginine residue at position 5 of the PAR-1-AP and a conserved glutamic acid in ECL2 and from an additional interaction between the tethered ligand aromatic Phe43 ring and the Ser89 side chain in the P85AFIS89 sequence at the C terminus of the PAR-1 exodomain (Figs. 1 and 2). However, there also is evidence that the precise docking sites for (or activation mechanisms triggered by) soluble and tethered ligands may differ. Although these differences in surface contact points for soluble and tethered ligands, in the context of the relatively unfavorable energetics for PAR-1 activation by soluble ligands, might be predicted to hinder efforts to develop therapeutically useful small-molecule PAR-1 antagonists, early screens identified BMS-200261 as a potent PAR-1 agonist. The limitation of compounds related to BMS 200261 is that they also exert agonist activity at PAR-2, an observation not altogether surprising given the high degree of sequence homology between the ECL2 (putative tethered ligand-binding) sequences of PAR-1 and PAR-2 (Fig. 3) as well as evidence that the human PAR-1 tethered ligand sequence SFLLRN is a potent agonist at PAR-2. PAR-1–selective activation has been accomplished with the *Xenopus laevis* PAR-1 tethered ligand sequence (TFLLRN, which carries a position 1 Ser→Thr substitution). Likewise, RWJ-56110 (Zhang et al., Fig. 1. Schematic representation of the topology of PAR-1. Functionally important sequences in the N-terminal exodomain, such as the P4–P1 residues that influence thrombin binding/catalysis (blue), the tethered ligand sequence (green), the hirudin-like high-affinity thrombin-binding site (pink), the acidic cluster (red), and the putative N-terminal exodomain ligand binding site (purple), are depicted. Ile88, Ser89, and Arg96 in the putative N-terminal exodomain ligand binding site (represented by gray-filled circles) are sites at which alanine substitution results in a profound defect in PAR-1 activation by SFLLRN but not thrombin (Blackhart et al., 2000). The location of potential thrombin, APC/FXα, trypsin, cathepsin G, elastase, proteinase 3, and plasmin cleavage sites on PAR-1’s N-terminal exodomain are indicated (Renesto et al., 1997). Serine/threonine residues that are potential sites for G protein-coupled receptor kinase-mediated phosphorylation in the C-tail are highlighted by the red-filled circles. A tyrosine-based YXXL sorting motif recently implicated in PAR-1 trafficking and internalization is highlighted in red circles.
PARs are endowed with two unique regulatory features as a result of their distinctive proteolytic activation mechanism. First, PAR-1 need not be selective for thrombin. Rather, PAR-1 is activated by any serine protease that cleaves the N terminus Arg41-Ser42 bond (including coagulation factors upstream of thrombin such as factor VIIa and factor Xa and the anticoagulant-activated protein C). Second, PAR-1 cleavage need not lead to receptor activation. Rather, nonproductive cleavage events at sites that amputate the tethered ligand sequence render PAR-1 unresponsive to subsequent proteolytic activation (although PAR-1 cleaved in this manner generally remains otherwise structurally intact and fully responsive to SFLLRN). It has been speculated that nonproductive cleavage events fulfill a particularly important role (in addition to the traditional phosphorylation/internalization desensitization mechanisms) to terminate signaling by activated PARs, which irreversibly carry their tethered ligand. Indeed, a recent study linked PAR-1 activation (or activation of its downstream effector, protein kinase C) to regulated PAR-1 N-terminal exodomain shedding, although the physiological importance of this process as a mechanism to terminate/modulate thrombin-dependent PAR-1 activation has not yet been established (Ludeman et al., 2004). Cathepsin G, a protease released from activated neutrophils at sites of injury and inflammation, is another example of a protease capable of amputating the PAR-1–tethered ligand. Although cathepsin G can cleave the Arg41-Ser42 bond (i.e., activate PAR-1) in heterologous overexpression systems, nonproductive cleavage events at sites that amputate the tethered ligand seem to predominate in the physiological context (Molino et al., 1995). Finally, plasmin, an enzyme that is released from inactive precursor plasminogen by thrombolytics such as tissue plasminogen activator and that plays an important role to cleave fibrin and dissolve clots, disables PAR-1 by cleaving the exodomain at one or more basic arginine/lysine residues (Fig. 1) (Jacques and Kuliopulos, 2003). It is noteworthy that most nonproductive cleavage events have been identified for the human PAR-1 sequence; species-dependent differences in primary amino acid sequences (or glycosylation patterns) could influence this process and only infrequently have been considered.

**PAR-2.** PAR-2 is a trypsin-activated receptor (i.e., the only PAR not effectively cleaved by thrombin) that is detected in a wide range of tissues; PAR-2 is particularly abundant in tissues exposed to the extracellular environment (i.e., the gastrointestinal tract and airways). Like PAR-1, PAR-2 is activated via limited proteolysis of its N-terminal exodomain or by a synthetic peptide corresponding to the first six amino acids of the newly exposed N terminus of the cleaved receptor (SKGR↓SLIGRL) (Table 1). Initial structure-activity relationship studies identified a functionally important charge-charge interaction between the basic position 5 residue in the PAR2-AP and a conserved ECL2 glutamic acid residue analogous to the mechanism described for PAR-1. However, more recent mutagenesis studies reveal striking differences in the structure-activity relationships for soluble and tethered ligands, raising important questions regarding the nature of the tethered ligand domain–ECL2 docking interaction (Osovskaya and Bunnett, 2004). A simple intramolecular activation model also does not explain the unusual pharmacology of a recently described human PAR-2 polymorphic variant (PAR-2-F240S, involving a Phe3240→Ser mutation at position 240 of ECL2) (Fig. 3 and Table 2) (Compton et al., 2000)). Compared with WT-PAR-2, PAR-2-F240S displays markedly reduced sensitivity to trypsin, impaired activation by rodent and human PAR-2-AP sequences (SLIGRL and SLIGKV, respectively), but ~4-fold increased sensitivity to the PAR-2–selective agonist trans-cinnamoyl-LIGRLO-NH₂. TLIGRL (a PAR-2-AP sequence with a position 1 Ser→Thr substitution) also is relatively selective for PAR-2-F240S; TLIGRL is a very weak agonist for WT-PAR-2. Finally, SFLLRN (a PAR-
1-AP) exhibits similar potency at WT-PAR-2 and PAR-2-F240S, whereas TFLLR-NH₂ (the Ser→Thr-substituted PAR-1-AP) and trans-cinnamoyl-YGPKF (a PAR-4-AP derivative) selectively activate PAR-2-F240S (not WT-PAR-2). The altered pharmacology of the PAR-2-F240S variant raises serious questions regarding the structure of endogenous PAR-2 peptide ligands in tissues and emphasizes the importance of considering polymorphisms in the design and clinical application of PAR-directed pharmaceuticals. In this regard, 2-furoylated derivatives of the native PAR-2-AP have been identified as effective in vivo PAR-2 agonists. 2-Furoylated LIGRL-NH₂ is the most potent furoylated PAR-2-AP compound synthesized to date. It displays high intrinsic agonist activity and resists degradation by aminopeptidases (Kawabata et al., 2004), although its activity at the PAR-2-F240S polymorphic variant has not been considered.

Pancreatic trypsin is presumed to be the physiological activator of PAR-2 in the intestinal lumen; trypsin prematurely released from trypsinogen also is presumed to activate PAR-2 in the inflamed pancreas. At sites not exposed to pancreatic trypsin, PAR-2 cleavage has been attributed to 1) extrapancreatic forms of trypsin; 2) trypsinase, a serine protease that selectively activates PAR-2 (not PAR-1) and is released in high concentrations by degranulating mast cells; 3) membrane-type serine protease-1, a transmembrane protein that contains an extracellular protease domain and is coexpressed with PAR-2 in certain tissues; 4) coagulation proteases upstream of thrombin such as factors VIIa and Xa; and 5) airborne allergens, such as the dust mite serine proteases Der 3 and Der 9, that cleave PAR-2 on airway epithelial cells, leading to the release of proinflammatory mediators and airway hypersensitivity; and 6) proteases elaborated by bacterial pathogens such as Porphyromonas gingivalis, Pseudomonas aeruginosa, or Legionella pneumophila. Of interest, P. gingivalis is the major causative agent of adult periodontal disease; it is reported to escape into the bloodstream and infect atherosclerotic plaques during routine oral hygiene procedures in patients with severe periodontal disease. The observation that P. gingivalis releases a protease that cleaves PAR-2 may explain the epidemiological link between periodontal disease and increased cardiovascular risk. As a group, the rather eclectic list of proteases that cleave PAR-2

---

**TABLE 1**

<table>
<thead>
<tr>
<th></th>
<th>PAR-1</th>
<th>PAR-2</th>
<th>PAR-3</th>
<th>PAR-4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary activating protease (EC₅₀)</strong></td>
<td>Thrombin (50 pM)</td>
<td>Trypsin (1 nM)</td>
<td>Thrombin (0.2 nM)</td>
<td>Thrombin (5 nM)</td>
</tr>
<tr>
<td><strong>Other activating proteases</strong></td>
<td>Trypsin</td>
<td>FXa</td>
<td>FXa</td>
<td>Trypsin</td>
</tr>
<tr>
<td><strong>Inactivating proteases</strong></td>
<td>Cathepsin G</td>
<td>Plasmin</td>
<td>Cathepsin G</td>
<td>Plasmin</td>
</tr>
<tr>
<td><strong>Cleavage sequence</strong></td>
<td>LDPR</td>
<td>SLIGKV</td>
<td>MTSP1</td>
<td>LPIK</td>
</tr>
<tr>
<td><strong>Tethered ligand sequence</strong></td>
<td>SFLLRN (h)</td>
<td>SLIGRL (h)</td>
<td>SFLLRN (m, r)</td>
<td>TFRGAP (h)</td>
</tr>
<tr>
<td><strong>Hirudin-like sequence</strong></td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td><strong>Agonist peptides (generally as amides)</strong></td>
<td>SFLLRN</td>
<td>SLIGK</td>
<td>None known</td>
<td>GYPGKF</td>
</tr>
<tr>
<td><strong>Antagonists</strong></td>
<td>BMS-200261</td>
<td>RWJ-56110</td>
<td>19p12 (h)</td>
<td>SB3.3 (m)</td>
</tr>
<tr>
<td><strong>Chromosome</strong></td>
<td>5q13 (h)</td>
<td>5q13 (h)</td>
<td>5q13 (h)</td>
<td>19p12 (h)</td>
</tr>
</tbody>
</table>

**MMP**, matrix metalloproteinase; **TACE**, tumor necrosis factor-a converting enzyme.

*Results examining the role of PAR-4 as a cellular cathepsin G receptor are inconsistent (see text).*

---

**Fig. 3.** Sequence alignment of the conserved extracellular loop 2 region in the four known PARs. Residues that are identical in PAR-1, PAR-2, and PAR-3 (and in some cases PAR-4) are depicted in blue. Residues conserved in PAR-2 and PAR-3 (and in some cases PAR-4, but not PAR-1) are shown in yellow. The acidic glutamic acid that is believed to dock the tethered ligand position 5 arginine residue is shown in red. Potential N-linked glycosylation sites are highlighted in green. The location of the human PAR-2-F240S polymorphism is depicted in purple.
has been taken to suggest that PAR-2 has evolved its unique pharmacology to sample the extravascular environment at defensive barriers (such as the gastrointestinal tract and airways), detect foreign proteases (released by ingested bacterial pathogens or inhaled irritants), and trigger primary inflammatory responses. In keeping with this concept, PAR-2 expression is up-regulated by proinflammatory mediators (such as tumor necrosis factor-α and interleukin-1). PAR-2 influences the perception of painful stimuli and plays a critical role in various acute and chronic inflammatory processes (Vergnolle et al., 2001).

PAR-3/PAR-4. PAR-3 and PAR-4 are the most recently cloned “thrombin receptors”. Both contain N-terminal serine protease cleavage sites, but their pharmacological properties and functions are quite different. PAR-3 contains an N-terminal hirudin-like high-affinity thrombin-binding domain (FEEFP, analogous to the site on PAR-1) (Fig. 2). However, PAR-3 is the only known PAR that is not activated by a synthetic peptide corresponding to its putative tethered ligand. A detailed structural analysis of PAR-3 provides a clue to its distinct role in thrombin signaling. Unlike PAR-1 and PAR-4, which contain $P_2$ position prolines that optimize their structural specificity for thrombin, mouse PAR-3 lacks a proline residue in the $P_1$-$P_4$ sequence (L$^{34}$TIK) and is a relatively poor thrombin substrate. Human PAR-3 has a $P_3$ proline that actually sterically hinders its interaction with and cleavage by thrombin. These properties of PAR-3 make sense in the context of the current model that assigns PAR-3 a function as a coreceptor for PAR-4 in mouse platelets.

PAR-4 is activated via thrombin-dependent cleavage of the PARP $\rightarrow$ GYPGQV site or by synthetic peptides corresponding to the tethered ligand sequence exposed after thrombin cleavage. However, PAR-4 activation requires relatively high thrombin concentrations (~50-fold higher than the thrombin concentrations required to activate PAR-1), presumably because PAR-4 lacks a hirudin-like high-affinity thrombin-binding domain (Fig. 2). The AP concentrations required to activate PAR-4 also are substantially higher than those required for PAR-1 or PAR-2 activation by their cognate APs. However, agonist potency is substantially improved, without losing specificity for PAR-4, by substituting an alanine at position 1 in the AP sequence (AYPGKF) (Table 1).

PAR-4 responses tend to be slow in onset and are sustained relative to the rapid and transient responses typically elicited by PAR-1. The relatively slow activation kinetics for PAR-4 are believed to be the direct consequence of the relatively slow rate of PAR-4 cleavage by thrombin. Current models suggest that the coexpression of multiple thrombin-sensitive PARs with distinct pharmacological properties allows for graded responses to a wide range of thrombin concentrations and/or thrombin-dependent responses that follow different temps, involve distinct intracellular effectors, or are localized to different membrane subdomains. As noted, multiple PARs also could enable responses to a wide repertoire of proteases (in addition to thrombin). Indeed, PAR-4 has been characterized variably as a cellular receptor for trypsin and plasmin (Sambrano et al., 2000; Quinton et al., 2004). In the case of plasmin, the kinetics of PAR-4 cleavage are relatively slow. However, the generation of plasmin for protracted intervals (the goal of treatment for stroke or deep vein thrombosis) could result in the slow/indolent activation of PAR-4 and a paradoxical increase in thrombus formation as a result of platelet activation. Finally, PAR-4 also has been reported to mediate the cellular actions of cathepsin G in an oocyte expression system (Sambrano et al., 2000), although subsequent studies failed to detect PAR-4-mediated actions of cathepsin G in murine platelets or thrombin-responsive PAR-1$^{-/-}$ fibroblasts that overexpress PAR-4 (see below) (Sabri et al., 2003a). These discrepant results could suggest that PAR-4 cleavage by cathepsin G might be influenced by factors such as species differences in primary amino acid sequence or post-translational modification, which deserve closer study.

### Cardiovascular Actions of PARs

**PAR Actions in the Vasculature.** The critical role of PAR-1 in vascular events was exposed when the PAR-1 gene was disrupted in mice. PAR-1$^{-/-}$ mice display a partial embryonic lethal phenotype. Approximately 50% of PAR-1$^{-/-}$ embryos succumb to a fatal bleeding event between embryonic days 9.5 and 12.5; the remainder show no obvious phenotype. It is noteworthy that a molecular strategy which drives PAR-1 expression only in endothelial cells (using the endothelial-specific Tie2 promoter enhancer) is sufficient to rescue this phenotype, providing strong evidence that PAR-1 is required for normal vascular development in the embryo (Griffin et al., 2001). Consistent with the role of PAR-1 in embryonic blood vessel growth and differentiation, thrombin signaling via PAR-1 also has been implicated in tumor neo-vascularization.

PARs also regulate vascular tone. A number of laboratories have described PAR-triggered cardiovascular responses in intact animal models. In rodents, PAR-1-AP infusion leads to a biphasic blood pressure response; a rapid/transient hypertensive response (mediated by NO) is followed by a more sustained increase in blood pressure that is presumed to reflect direct activation of PAR-1 on vascular smooth muscle cells. In contrast, PAR-2-AP infusion only induces hypotension in these models (Cicala et al., 1999). The mechanism(s) for PAR-dependent vasoregulation have been explored largely using in vitro preparations of precontracted vessels. Here, PAR-1 and PAR-2 both induce vasorelaxation via an endothelial-dependent mechanism that generally is attributed to an NO-dependent process in large vessels and an NO-independent process (that in many cases involves a cyclooxygenase product) in smaller caliber vessels. In endothelium-denuded vessels, PAR-1 induces a contractile response via an action at the underlying smooth muscle layer. These PAR-dependent actions generally are assumed to gain importance as mechanisms that regulate local blood flow at sites of

<table>
<thead>
<tr>
<th>Allele frequency</th>
<th>PAR-2-Phe$^{240}$</th>
<th>PAR-2-Ser$^{240}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activating protease</td>
<td>Trypsin</td>
<td>tc-LIGRLO</td>
</tr>
<tr>
<td>Peptide agonist</td>
<td>SLIGRL</td>
<td>TLIGRL</td>
</tr>
<tr>
<td></td>
<td>SLIGKV</td>
<td>SFLLRN</td>
</tr>
<tr>
<td></td>
<td>SFLLRN</td>
<td>TFLR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>tc-YGPKF</td>
</tr>
</tbody>
</table>
tissue damage, because PAR-1−/− and PAR-2−/− mice exhibit no obvious abnormalities in blood pressure regulation (at least at baseline, under unstressed conditions). However, there is recent evidence that PAR-2 induces arterial and venous dilatation in vivo in healthy humans, and lipopolysaccharide (which up-regulates PAR-2 expression) can markedly sensitize animals to the in vivo hypotensive effects of PAR-2 agonists (Cicala et al., 1999; Robin et al., 2003). These results suggest that PAR-2 activation could contribute to blood pressure dysregulation during sepsis, endotoxemia, or other states associated with serine protease activation.

PARs also participate in the response to vascular injury, a process most effectively examined in PAR-1−/− mice, where PAR-1–mediated actions of thrombin in the vasculature can be distinguished from the PAR-3/PAR-4–mediated actions of thrombin in platelets. PAR-1−/− mice exhibit reduced neointimal proliferation and restenosis when subjected to various models of vascular injury (e.g., balloon injury and endothelial denudation), suggesting that PAR-1 contributes to vascular injury responses and restenosis. Vascular remodeling has been viewed as the consequence of a series of highly orchestrated PAR-1–triggered responses. PAR-1 alters junctional complexes between endothelial cells, leading to increased monolayer permeability and the extravasation of plasma proteins. PAR-1 recruits platelets and leukocytes to injured surfaces by inducing the expression of inflammatory cytokines and adhesion molecules and increasing the production of platelet-activating factor, prostanoioids, and nitric oxide. PAR-1 promotes vascular remodeling by stimulating vascular endothelial and smooth muscle cell proliferation directly and indirectly via the production of growth factors, as well as by promoting the synthesis and release of matrix proteins and matrix-degrading metalloproteinases. It is noteworthy that PAR-2 mimics some (but not all) of the cellular actions of PAR-1. Although PAR-2 does not mimic the in vitro effect of PAR-1 to increase endothelial monolayer permeability, PAR-2 stimulates vascular endothelial cell mitogenesis in vitro, and it exerts a proangiogenic action which is not accompanied by significant inflammatory changes, in vivo normoperfused (nonischemic) skeletal muscles (Mirza et al., 1996; Milia et al., 2002). PAR-2 also is reported to potentiate reparative angiogenesis and enhance limb salvage in a hind limb ischemia model (Milia et al., 2002). These proangiogenic actions of PAR-2 would be amplified in an ischemic milieu, in which increased endothelial cell PAR-2 expression and the accumulation of PAR-2–bearing leukocytes would lead to the release of proangiogenic substances (Milia et al., 2002). Finally, there is recent evidence that PAR-4 may play an ancillary role, with PAR-1, in thrombin-dependent signaling events in the vascular endothelium in mice (Kataoka et al., 2003). The clinical relevance of this observation is uncertain, because PAR-4 function seems to be highly species- and/or model-specific; PAR-4 responses generally have not been detected in human endothelial cells (O’Brien et al., 2000; Kataoka et al., 2003). Together, these results implicate PARs as regulators of events that influence the evolution of atherosclerosis, ischemic tissue injury, and tumor angiogenesis.

PAR Actions in the Heart

PAR-1 Actions in Cardiomyocytes. PAR-1 activation by thrombin triggers a range of signaling events in cardiomyocytes that lead to rapid changes in electrical/mechanical function and could contribute to the genesis of the electrophysiological derangements observed in the setting of myocardial ischemia and infarction. Thrombin increases spontaneous automaticity and/or elevates [Ca2+]i in a range of cardiomyocyte preparations (Chien et al., 1990; Albitz et al., 1992; Jiang et al., 1996, 1998). Thrombin also prolongs the action potential duration and increases cesium-induced early afterdepolarizations in isolated canine Purkinje fibers; thrombin induces proarrhythmic events during early reperfusion in intact adult rat hearts (Steinberg et al., 1991; Jacobsen et al., 1996). PAR-1 activation also has been linked to a diacylglycerol/protein kinase C pathway that activates Na+–H+ exchange and increases contractile performance in adult rat cardiomyocytes (Yasutake et al., 1996). However, some thrombin-inducedionic derangements cannot be attributed to phospholipid-derived second-messenger molecules. For example, the effect of thrombin to mobilize intracellular calcium in neonatal rat cardiomyocytes and Chinese hamster ovary cells is not blocked by a phospholipase C inhibitor; it cannot be attributed to the conventional inositol 1,4,5-trisphosphate–dependent mechanism (Jiang et al., 1996).

It may be no accident that most cardiac actions of PAR-1 have been described in intact tissue preparations or cardiomyocyte cultures. Although we and others have linked PAR-1 activation to an increased contractile response in adult cardiomyocytes acutely isolated from the intact ventricle (Yasutake et al., 1996; Jiang et al., 1998), PAR-1 responses typically are detected only at rather high AP concentrations in this preparation (an order of magnitude higher than the PAR-1–AP concentrations required to activate PAR-1 in other preparations). The molecular basis for these differences in PAR-1 responsiveness is suggested by recent studies of another GPCR; we recently demonstrated that standard enzyme-based cardiomyocyte isolation protocols lead to limited proteolysis of β-adrenergic receptors (β-ARs) (Rybin et al., 2003). Limited proteolysis would activate, desensitize, and/or disable PAR-1 (and render cells hyporesponsive to SFLLRN and unresponsive to thrombin). In support of this formulation, low concentrations of SFLLRN, which are subthreshold in acutely isolated adult cardiomyocytes, increase the force of isometric contraction in intact adult rat papillary muscles (Jiang et al., 1998).

In keeping with the actions of PAR-1 as a potent mitogen for cells that maintain proliferative potential (such as vascular smooth muscle cells or fibroblasts), prolonged/persistent activation of PAR-1 has been linked to a series of morphological and molecular changes that are characteristic of the cardiomyocyte hypertrophic growth program; PAR-1 agonists increase protein content and cell size, increase sarcomeric organization, and induce early-immediate gene expression. It is noteworthy that PAR-1 agonists increase cell length but promote only a relatively minor increase in cell width; this morphology is characteristic of volume-overload–dilated cardiac hypertrophy (Sabri et al., 2000). In contrast, α1-AR agonists induce a uniform increase in cell dimension (cell
length and width), which is more akin to the changes observed in the setting of pressure-overload hypertrophy. The signaling mechanisms that distinguish these morphologically distinct forms of cardiac hypertrophy, which carry different prognoses when encountered in clinical practice, are not obvious because PAR-1 and α1-ARs activate many common effector pathways (PLC, ERK, c-Jun NH₂-terminal kinase, p38-MAPK, and Akt) (Fig. 4A). Nevertheless, some differences in the signaling molecules recruited by activated PAR-1 and α1-AR (that could impact the cardiac phenotype) have been identified. First, the α1-AR growth response is attributable exclusively to pathways emanating from Gαq. In contrast, PAR-1 promotes cardiac growth via dual pathways emanating from both Gαq and G12. This difference may be pertinent, because a genetic model of persistent G12 activation (caused by G12-coupled receptor overexpression) has been linked to a dilated form of cardiomyopathy in mice. The effect of PAR-1 to trigger a prominent increase in [Ca²⁺]i, [far in excess of the relatively minor calcium-mobilizing effects induced by α1-ARS (Jiang et al., 1996; Sabri et al., 2000)] also could contribute to the pathogenesis of a morphologically and functionally distinct form of cardiac hypertrophy. These and other mechanisms that might distinguish the hypertrophic signaling phenotypes induced by different GPCRs are the focus of ongoing research.

**Cardiac Actions of PAR-2.** PAR-2 activates a spectrum of biochemical and functional responses that largely mimic cardiomyocyte activation by PAR-1 (including PLC, ERK, p38-MAPK, increased [Ca²⁺]i, enhanced spontaneous automaticity, and elongated/dilated hypertrophy) in neonatal rat cardiomyocyte cultures (Sabri et al., 2000). The relevant PAR-2–activating protease in the heart has not been identified. However, mast cell tryptase is a likely candidate, given reports that mast cells can be identified between muscle fibers in normal ventricles, that mast cells are present in increased numbers in idiopathic and dilated cardiomyopathies (Patella et al., 1998), and that tissue tryptase levels are elevated to levels that could potentially trigger PAR-2 signaling in certain cardiac syndromes (Patella et al., 1998). It is noteworthy that the effect of tryptase to activate PAR-2 is variably detected in different cell types. Cell-specific differences in PAR-2 activation by tryptase has been attributed to an N-linked glycosylation six residues away from the human PAR-2 cleavage site (13 residues away from the rat PAR-2 cleavage site); this glycosylation event seems to prevent PAR-2 activation by tryptase but not by trypsin (Compton et al., 2002). This additional mechanism to regulate PAR-2 signaling should be considered in future studies of cardiac PAR-2 actions.

PAR-2 agonists enhance the efficiency of ischemic preconditioning, improve myocardial functional recovery, and decrease the incidence of ventricular arrhythmias in an in vivo ischemia-reperfusion cardiac-injury model in rats (Napoli et al., 2000). The cardioprotective effects of PAR-2 would not necessarily have been predicted from literature that casts PAR-2 as an activator of proinflammatory events in many noncardiac tissues. However, the beneficial effects of PAR-2 have been attributed to PAR-2–dependent regulation of coronary vascular tone. PAR-2 agonists promote coronary vasodilation (via an endothelium-dependent, NO-independent mechanism), leading to improved perfusion of the compromised ventricle. The preserved PAR-2–dependent coronary vasodilatory response is in stark contrast to the reduced/absent responses to other endothelium-dependent vasodilators (such as acetylcholine and bradykinin) that characterize the endothelial dysfunction that develops during ischemia reperfusion (McLean et al., 2002). Up-regulation of PAR-2 expression in the setting of ischemia reperfusion and early atherosclerotic lesions has been offered as an explanation for the preserved PAR-2–induced vasodilatory response. Hence, PAR-2 represents a promising therapeutic target to influence the pathogenesis of in vivo ischemia-reperfusion injuries.

**Cardiac Actions of PAR-4.** PAR-4 was originally identified as a receptor that is expressed at low levels in the mouse...
heart; PAR-3 is not detected in the heart. However, recent studies localize PAR-4 mRNA to cardiomyocytes themselves (rather than cardiac fibroblasts) and identify cardiac actions for PAR-4 that are distinct from the cardiac actions of PAR-1 (Sabri et al., 2003b). PAR-4 activation leads to a modest increase in PLC and ERK activity and a weak hypertrophic response relative to the robust PLC/ERK responses and hypertrophy triggered by agonists for PAR-1 or α1-AR in this preparation (Fig. 4A). This is surprising (and unexplained) because PAR-4 agonists couple to a robust PLC/ERK response in PAR-1−/− lung fibroblasts that heterologously overexpress PAR-4. However, PAR-4 induces a rather strong activation of a nonreceptor Src tyrosine kinase-p38-MAPK cascade in cardiomyocytes. Studies in PAR-1−/− cardiomyocytes yield additional surprising evidence that the effect of thrombin to activate Src in cardiomyocytes is mediated exclusively by PAR-4 and not by PAR-1, as might be assumed from previous literature of the actions of thrombin in other cell types (Sabri et al., 2003b). Finally, studies in PAR-1−/− fibroblasts that heterologously overexpress PAR-4 show that PAR-4 couples to the activation of PLC, ERK, and p38-MAPK via a pathway that involves epidermal growth factor receptor (EGFR) transactivation. These studies suggest that PAR-4 may play a more general role to link thrombin stimulation to the activation of growth regulatory pathways mediated by receptor and nonreceptor tyrosine kinases.

The functional consequences of PAR-4 expression/activation in cardiomyocytes remain uncertain. We have speculated that PAR-4 plays only a minor role under normal physiological conditions, in which the cardiac responses to thrombin are mediated primarily by PAR-1. However, pathological conditions that render PAR-1 inactive, such as inflammation and the elaboration of proteases that amputate N-terminal–tethered ligand of PAR-1, might shift the balance of signaling by PAR-1 and PAR-4. Under these conditions, unopposed PAR-4 activation of the Src/p38-MAPK pathway might lead to more adverse functional outcomes.

**PAR-1 Actions in Cardiac Fibroblasts.** Cardiac fibroblasts are a major cellular component of intact ventricular myocardial tissue. Cardiac fibroblast activation by GPCR agonists (generally angiotensin II and endothelin) has been linked to proliferation and the synthesis of matrix components, responses that are essential for normal scar formation at sites of myocardial injury/infarction. However, excessive cardiac fibroblast activation (in the setting of hypertension) can lead to diastolic stiffness and mechanical failure; exuberant fibroblast-dependent synthesis of paracrine growth factors or matrix components also can lead to noncontractile fibrotic scars that disrupt the normal transmission of electrical impulses. Recent studies identify PAR-1 as a functionally important GPCR in cardiac fibroblasts; cardiac fibroblasts do not express PAR-2, PAR-3, or PAR-4. PAR-1 activates a spectrum of signaling responses (including PLC, calcium, ERK, p38-MAPK, and Akt) that lead to increased cardiac fibroblast proliferation (Sabri et al., 2002).

The detailed signaling mechanisms activated by PAR-1 in cardiomyocytes and cardiac fibroblasts are quite distinct (Fig. 4). Most notably, transactivation of EGFRs (or other receptor tyrosine kinase family members) plays little to no role in PAR-1 signaling to ERK and hypertrophy in cardiomyocytes. In contrast, nonreceptor tyrosine kinases (including Src and Fyn) and EGFR play a pivotal role in linking PAR-1 to the stimulation of ERK, p38-MAPK, and Akt and increased DNA synthesis (as a measure of proliferation) in cardiac fibroblasts (Sabri et al., 2002). These results emphasize the highly contextual, cell-specific nature of PAR-1 signaling in the heart. Another striking difference between PAR-1 signaling responses in cardiomyocytes and cardiac fibroblasts relates to Akt. PAR-1 agonists induce a very robust increase in Akt (via EGFR transactivation) in cardiac fibroblasts; in contrast, PAR-1 does not significantly transactivate EGFR family members and leads to only a very minor increase in Akt in cardiomyocytes (Sabri et al., 2002). These studies are consistent with the notion that robust GPCR-dependent Akt activation is confined to cells (and GPCRs) that support the EGFR transactivation mechanism. Given the importance of Akt as a therapeutic target for heart failure, progress toward identifying the mechanisms that enable GPCR networking to EGFR transactivation (and Akt activation) holds profound clinical significance.

**Cardiomyocyte Activation by Proteases Other Than Thrombin.** The endogenous PAR activators in the heart remain uncertain. Although cardiomyocyte PARs may be activated by thrombin in the setting of hemorrhagic infarction, in which the endothelial barrier is broken and cardiomyocytes come into direct contact with blood-borne substances, most myocardial events are not accompanied by hemorrhage into the myocardium. As noted, mast cell degranulation might lead to the release of serine proteases such as tryptase and to the activation of PAR-2. The border zone adjacent to a myocardial infarction (an area characterized by intense interstitial inflammation and important local changes in gene expression, cardiomyocyte hypertrophy, contractile dysfunction, and apoptosis) might be another region prone to PAR signaling events. From published evidence that PAR-4 can function as a cellular receptor for neutrophil-derived cathepsin G (in the context of evidence that cardiomyocyte express functional PAR-4), we recently considered whether cathepsin G exerts direct cardiac actions (Sabri et al., 2003a). We identified cathepsin G as a potent cardiomyocyte agonist. Cathepsin G induces a spectrum of acute signaling responses, including activation of PLC, ERK, and p38-MAPK, stimulation of Akt, and changes in contractile function, that in many respects mimic the cardiac actions of thrombin. However, detailed studies yielded several lines of evidence to argue that the cardiac actions of cathepsin G cannot be attributed to the activation of any known PAR. First, we found that cathepsin G induces a similar increase in PLC and p38-MAPK activity in WT and PAR-1−/− cardiomyocytes; these results effectively exclude a role for PAR-1 in cardiac cathepsin G responses, although cathepsin G-dependent disabling cleavage events for both human and mouse PAR-1 sequences were identified (Sabri et al., 2003a). Second, we found that cathepsin G disrupts the sarcromeric structure and induces progressive loss of cell-cell and cell-matrix contacts and leads to cell rounding and detachment from underlying matrix (i.e., detachment-induced apoptosis or anoikis) (Sabri et al., 2003a). This morphology is strikingly different from the hypertrophic phenotype induced by conventional PAR agonists. However, it is quite reminiscent of the cathepsin G-induced changes reported in endothelial cell monolayers, in which cathepsin G impairs monolayer barrier function and exposes the potentially thrombogenic underlying extracellular matrix (Iacoviello et al., 1995). Third, cathepsin G activates execu-
tioner caspases that cleave survival signals (focal adhesion kinase and Akt) and sarcomeric proteins (troponin T) in cardiomyocytes; none of these events are observed in cells exposed to thrombin. Finally, we could not detect cathepsin G responses in PAR-1/−/− fibroblasts that overexpress either PAR-1 or PAR-4 and exhibit robust responses to thrombin. Together, these results raise serious doubts that the action of cathepsin G in cardiomyocytes (and probably other adherent cell types) can be attributed to the activation of a known PAR. The precise cellular target(s) for the action of cathepsin G has not yet been identified. It is interesting that cathepsin G has been reported to degrade matrix components, either directly or indirectly via the cleavage/activation of latent matrix-degrading metalloproteinases. The role of matrix metalloproteinases versus other potential targets for the action of cathepsin G is a focus of ongoing studies.

Future Challenges. Initial efforts to clone a thrombin receptor were fueled by the expectation that thrombin receptor antagonists could be used to interfere with thrombin’s cellular actions without increasing bleeding diathesis by inhibiting fibrin formation. The cloning of four PARs whose roles extend to a wide range of cellular processes has identified novel therapeutic targets for a variety of common clinical disorders. This extends to the heart, in which PAR-1 and PAR-2 influence cardiomyocyte electrical and mechanical events and PAR-1, PAR-2, and PAR-4 promote cardiac structural remodeling (through actions in both the cardiomyocytes themselves as well as the supporting cardiac fibroblasts). Despite substantial progress toward understanding the activation mechanisms and functions of individual PARs in the heart, many important questions remain outstanding. The challenges for future research are to identify the physiologically relevant proteases that activate and disarm cardiac PARs, determine whether the heart might be a source of endogenous peptide ligands that locally regulate PARs, determine whether PAR expression is influenced by the hypertrophic growth program or cardiac failure, explore roles for polymorphic variants of PARs as disease modifiers, and develop more potent agonists and antagonists to regulate signaling by individual PAR family members (including the in vivo context). As a whole, these types of studies will lay the groundwork to consider PARs as therapeutic targets in newer strategies to prevent and treat the functional and structural abnormalities that result from cardiac injury and inflammation.

References


Address correspondence to: Dr. Susan F. Steinberg, Department of Pharmacology, College of Physicians and Surgeons, Columbia University, 630 West 168 Street, New York, NY 10032. E-mail: sfs1@columbia.edu